NEW

Butterfly Files Motion to Dismiss Claims in FUJIFILM Sonosite Legal Action

Butterfly Network Inc. has filed a motion to dismiss claims and specific patents from a complaint for patent infringement lawsuit filed on March 9, 2022, by FUJIFILM Sonosite Inc. Butterfly believes the lawsuit alleging infringement of U.S. Patent Nos. 7,169,108;...

ARTIS icono ceiling Angiography System Earns FDA Clearance

Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the ARTIS icono ceiling, a ceiling-mounted angiography system designed for a wide range of routine and advanced procedures in interventional radiology (IR) and cardiology. The...

New Fixed X-ray System Brings ‘Personal Assistant’ to Radiology Departments

GE Healthcare released its most advanced fixed X-ray system yet, the next-generation Definium 656 HD. Leading GE Healthcare’s portfolio of fixed X-ray products, this latest generation of the overhead tube suspension (OTS) system delivers consistent, highly automated,...

Exo Acquires Medo AI

Exo (pronounced “echo”), a pioneering health information and medical devices company, has announced that it is acquiring Medo, a Canadian developer of artificial intelligence (AI) technology, to make ultrasound imaging faster and simpler to use. By integrating Medo’s...

Elekta and Philips Deepen Oncology Partnership

Elekta and Philips Deepen Oncology Partnership

Elekta and Royal Philips have signed agreements to deepen their existing strategic partnership to advance comprehensive and personalized cancer care through precision oncology solutions.

The extended collaboration builds on the two companies’ successful cooperation in the fast-emerging field of magnetic resonance (MR)-guided adaptive radiation therapy. Through deeper cross-portfolio collaboration, Elekta and Philips will utilize their complementary capabilities to further improve patient care.

Benefiting patients throughout the care pathway

Oncology care is transforming, driven by an increasingly precise diagnosis of each tumor, and a continuously expanding range of therapy options. To fully capitalize on these opportunities, healthcare providers require integrated solutions throughout the entire cancer care pathway, from diagnosis to treatment and follow-up.

This integrated approach has the potential to provide:

  • Quicker, more accurate visualization of the tumor
  • Easier decision of optimal treatment strategy
  • Earlier assessment of therapy response
  • More effective and efficient therapy delivery

The strengthened strategic partnership intends to further deliver a superior experience in diagnosis and adaptive, personalized treatments for clinicians, shorter treatment times and more precise therapy for patients, and lowered costs of care for healthcare providers.

“I expect this extended partnership to unlock opportunities that will provide better outcomes for people with cancer,” said Gustaf Salford, Elekta’s President and CEO. “Together, we’ll combine advanced informatics and image-guided RT solutions to deliver greater precision in oncology. This means easier selection by clinicans of the optimal treatment strategy and more efficient and effective therapy delivery.”

“To capitalize on the opportunities presented by increasingly precise diagnosis and the fast-expanding range of therapies available for cancer patients, it’s essential to provide integrated systems and solutions that provide the right insights at the right time throughout each patient’s care journey,” said Kees Wesdorp, Chief Business Leader of Precision Diagnosis at Philips. “By deepening our already-successful collaboration with Elekta, we will accelerate towards our goal of providing clear care pathways and predictable outcomes for every cancer patient. Today’s announcement is an important next step in the implementation of our strategy in precision diagnosis.”

In this preferred, although non-exclusive, partnership, Elekta and Philips will leverage their capabilities to pursue integrated vendor-agnostic solutions, enhancing interoperability between the two parties’ systems and software in order to drive precision in oncology.

Previous

Next

Submit a Comment

Your email address will not be published.